Mode
Text Size
Log in / Sign up
N/A Completed N=256 Randomized Double-blind Treatment

Montelukast in Pediatric Patients Aged 6 to 24 Months With Asthma--Safety Study (0476-176)

Source: ClinicalTrials.gov NCT00943683 ↗
Enrolled (actual)
256
Serious AEs
3.1%
Results posted
Jun 2010
Primary outcomePrimary: Number of Clinical Adverse Experiences (CAEs) Reported by Patients During the 6-weeks of Treatment — 62; 132; 19; 43 Participants

Summary

A study of Montelukast compared to placebo in asthmatic children aged 6-24 months.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Clinical Adverse Experiences (CAEs) Reported by Patients During the 6-weeks of Treatment
62; 132; 19; 43 —

Eligibility Criteria

Inclusion Criteria

  • Patient is in good, stable health
  • Patient has been fed solid foods for at least 1 month
  • Patients had at least 3 episodes of asthma or asthma-like symptoms, all occurring after 8 weeks of age; at least one within 6 months of the Prestudy Visit
  • Patients had to be in need of a controller therapy according to criteria established in the Global Initiative for Asthma (GINA) guidelines

Exclusion Criteria

  • Patient was hospitalized at the start of the study or required a visit to the emergency room due to asthma with in past 2 weeks
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00943683). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search